Haloperidol (Haloperidol)

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Active substanceHaloperidolHaloperidol
Similar drugsTo uncover
  • Haloperidol
    pills inwards 
    ALSI Pharma, ZAO     Russia
  • Haloperidol
    solution w / m 
    MOSHIMFARM PREPARATES them. N.А.Semashko, OJSC     Russia
  • Haloperidol
    solution w / m in / in 
    ATOLL, LLC     Russia
  • Haloperidol
    pills inwards 
    BIOKOM, CJSC     Russia
  • Haloperidol
    pills inwards 
    CANONFARMA PRODUCTION, CJSC     Russia
  • Haloperidol
    solution w / m in / in 
    Biocanol Farma GmbH     Germany
  • Haloperidol
    pills inwards 
    ORGANICS, JSC     Russia
  • Haloperidol
    solution w / m 
    BINNOFARM, CJSC     Russia
  • Haloperidol
    pills inwards 
    AVEKSIMA, JSC     Russia
  • Haloperidol
    pills inwards 
    OZONE, LLC     Russia
  • Haloperidol decanoate
    solution inwards 
    GEDEON RICHTER, OJSC     Hungary
  • Haloperidol-Acry®
    pills inwards 
    AKRIKHIN HFK, JSC     Russia
  • Haloperidol-ratopharm
    drops inwards 
    ratiofarm GmbH     Germany
  • Haloperidol-Richter
    pills inwards 
    GEDEON RICHTER, OJSC     Hungary
  • Haloperidol-Richter
    solution inwards w / m 
    GEDEON RICHTER, OJSC     Hungary
  • Haloperidol-Richter
    pills inwards 
    GEDEON RICHTER, OJSC     Hungary
  • Haloperidol-Ferein
    solution w / m in / in 
    BRYNTSALOV-A, CJSC     Russia
  • Senorm
    solution w / m 
    San Pharmaceutical Industries Co., Ltd.     India
  • Senorm
    solution w / m in / in 
    San Pharmaceutical Industries Co., Ltd.     India
    • Dosage form: & nbsppills
    Composition:
    1 tablet of 1.5 mg contains:
    active substance: haloperidol - 1.5 mg.
    Excipients: lactose monohydrate (sugar milk) - 76.5 mg, corn starch - 6.0 mg, povidone-K17 - 3.3 mg, microcrystalline cellulose - 10.0 mg, magnesium stearate - 0.7 mg, pregelatinized starch - 2, 0 mg.
    1 tablet of 5 mg contains:
    active substance: haloperidol - 5 mg.
    Excipients: lactose monohydrate (sugar milk) - 73.0 mg, corn starch - 6.0 mg, povidone-K17 - 3.3 mg, microcrystalline cellulose - 10.0 mg, magnesium stearate - 0.7 mg, pregelatinized starch - 2, 0 mg.
    Description:Tablets with a dosage of 1.5 mg: white or white with a slightly yellowish hue of color, a flat-cylindrical shape with a risk on one side and a facet on both sides.
    Tablets with a dosage of 5 mg: white or white with a slightly yellowish hue of color, biconvex.
    Pharmacotherapeutic group:Antipsychotic agent (antipsychotic)
    ATX: & nbsp

    N.05.A.D.01   Haloperidol

    Pharmacodynamics:Antipsychotic agent (neuroleptic), a derivative of butyrophenone. It has a pronounced antipsychotic effect, a sedative effect (in small doses has an activating effect) and a pronounced antiemetic effect.Causes extrapyramidal disorders, virtually no cholinoblocking effect.
    Sedative action is due to blockade of alpha-adrenergic receptors of the reticular formation of the brain stem; antiemetic effect - blockade of dopamine D2 receptors in the trigger zone of the vomiting center; hypothermic action and galactorrhea - blockade of dopamine receptors of the hypothalamus. Prolonged reception is accompanied by a change in the endocrine status, in the anterior pituitary gland prolactin production increases and decreases - gonadotropic hormones.
    Pharmacokinetics:Absorption if taken orally - 60%. The time to reach the maximum concentration (TСmах) for oral administration - 3 hours. The volume of distribution is 18 l / kg, the connection with plasma proteins is 92%. Easily passes through the histohematological barriers, including the blood-brain barrier (BBB).
    Metabolized in the liver, has the effect of "first pass" through the liver. In the metabolism of the drug, isoenzymes CYP2D6, CYRZAZ, CYRZA5, CYPZA7 take part. It is an inhibitor of CYP2D6. There are no active metabolites. The half-life (T 1/2) for oral intake is 24 hours (12-37 h).
    It is excreted with bile and urine: after ingestion with bile 15% are excreted, with urine - 40% (including 1% - unchanged). Penetrates into breast milk.
    Indications:- Acute and chronic psychoses accompanied by excitement, hallucinatory and delusional disorders, manic conditions, psychosomatic disorders.
    - Behavioral disorders, personality changes (paranoid, schizoid, and others), Gilles de la Tourette's syndrome, both in childhood and adults.
    - Tiki, Huntington's chorea.
    - Long-lasting and resistant to therapy vomiting, including associated with antitumor therapy, and hiccups.
    Contraindications:Hypersensitivity, severe oppression of the central nervous system (CNS) on the background of xenobiotic intoxication, coma of various genesis, CNS diseases, accompanied by pyramidal or extrapyramidal symptoms (including Parkinson's disease), pregnancy, lactation period, children's age (up to 3 years for this drug forms).
    Carefully:Decompensated diseases of the cardiovascular system (CVS) (including angina pectoris, intracardiac conduction disorders,prolongation of the Q-T interval, or a predisposition to this - hypokalemia, concomitant use of other drugs that may cause prolongation of the QT interval), epilepsy and convulsive conditions in the anamnesis, angle-closure glaucoma, hepatic and / or renal failure, hyperthyroidism with the phenomena of thyrotoxicosis), pulmonary-cardiac and respiratory failure (including chronic obstructive pulmonary diseases and acute infectious diseases), prostatic hyperplasia with a delay in urine, alcohol zm.
    Pregnancy and lactation:Contraindicated.
    Dosing and Administration:Inside, during or after a meal, with a full (240 ml) glass of water or milk, the initial dose for adults is 0.5 - 5 mg 2 - 3 times a day. If necessary, the dose is gradually increased to achieve the desired therapeutic effect (on average - up to 10-15 mg, with chronic forms of schizophrenia - up to 20-60 mg). The maximum dose is 100 mg / day. Duration of treatment - 2 - 3 months. Reduce the dose slowly, maintenance doses - 5-10 mg / day.
    Elderly or weakened patients at the beginning of treatment appoint inward, 0.5 to 2 mg 2 - 3 times a day.
    If it is necessary to use 0.5 mg of the drug, tablets with a lower dosage are recommended.
    Children 3-12 years old (or body weight 15-40 kg) with psychotic disorders - inside, 0.05 mg / kg / day in 2-3 divided doses; if necessary taking into account the tolerability dose is increased by 0.5 mg 1 time for 5-7 days to a total dose of 0.15 mg / kg / day. With nonpsychotic behavioral disorders, Tourette's disease - inside, first 0.05 mg / kg / day in 2-3 divided doses, then increase the dose by 0.5 mg once every 5-7 days to 0.075 mg / kg / day . With children's autism - inside, 0.025-0.05 mg / kg / day. To prescribe the drug in childhood it is advisable to use dosage forms for children, which allow to accurately dose the drug.
    If there is no effect within 1 month, treatment should not be continued.
    Side effects:From the nervous system: headache, dizziness, insomnia or drowsiness (varying degrees of severity), anxiety, anxiety, psychomotor agitation, fear, akathisia, euphoria, depression, epileptic seizures, in rare cases, exacerbation of psychosis, incl. hallucinations; extrapyramidal disorders; with long-term treatment - tardive dyskinesia (smacking lips, puffing cheeks,rapid and vermiform movements of the tongue, uncontrolled chewing movements, uncontrolled movements of the hands and feet), late dystonia (rapid blinking or spasms of the eyelids, unusual facial expression or position of the body, uncontrollable bending movements of the neck, trunk, arms and legs) and malignant neuroleptic syndrome , muscle rigidity, difficulty or rapid breathing, tachycardia, arrhythmia, increase or decrease in blood pressure (BP), increased sweating, urinary incontinence, convulsive disorders, oppresses of consciousness).
    From the cardiovascular system: when used in high doses - reduced blood pressure, orthostatic hypotension, arrhythmias, tachycardia, changes in the ECG (prolongation of the Q-T interval, signs of flutter and fibrillation of the ventricles).
    From the digestive system: when used in high doses - decreased appetite, dry mouth, hypo-salivation, nausea, vomiting, diarrhea or constipation, impaired liver function, until the development of jaundice.
    From the hematopoiesis: rarely - temporary leukopenia or leukocytosis, agranulocytosis, erythropenia and a tendency to monocytosis.
    From the genitourinary system: retention of urine (with hyperplasia of the prostate gland), peripheral edema, pain in the mammary glands, gynecomastia, hyperprolactinaemia, violation of the menstrual cycle, decreased potency, increased libido, priapism.
    From the sense organs: cataract, retinopathy, blurred vision.
    Allergic reactions: maculopapular and acne-like skin changes, photosensitization, rarely - bronchospasm, laryngospasm.
    Laboratory indicators: hyponatremia, hyper- or hypoglycemia.
    Other: alopecia, weight gain.
    Overdose:Symptoms: oppression of consciousness, rigidity of muscles, tremor, drowsiness, lowering blood pressure, sometimes - raising blood pressure. In severe cases - coma, respiratory depression, shock.
    Treatment: when ingested - gastric lavage, Activated carbon.
    With respiratory depression - IVL. To improve blood circulation, intravenously injected plasma or albumin solution, norepinephrine. Epinephrine in these cases, use is strictly prohibited! To reduce extrapyramidal symptoms - central holinoblokatory and antiparkinsonian drugs. Dialysis is ineffective.
    Interaction:Increases the severity of the inhibitory effect on the CNS of ethanol, tricyclic antidepressants, opioid analgesics, barbiturates and hypnotic drugs, funds for general anesthesia.
    Strengthens the action of peripheral m-holinoblokatorov and most antihypertensives (reduces the effect of guanetidine due to its displacement from alpha-adrenergic neurons and suppression of its capture by these neurons).
    It inhibits the metabolism of tricyclic antidepressants and MAO inhibitors, while their (mutually) sedative effect and toxicity increase.
    With simultaneous use with bupropion reduces the epileptic threshold and increases the risk of major epileptic seizures.
    Reduces the effect of anticonvulsants (reducing the convulsive threshold with haloperidol).
    Weaken the vasoconstrictive effect of dopamine, phenylephrine, norepinephrine, ephedrine and eninephrine (blockade of alpha-adrenoreceptors by haloperidol, which can lead to a distortion of the action of epinephrine and a paradoxical decrease in blood pressure).
    Reduces the effect of antiparkinsonian drugs (antagonistic effect on dopaminergic structures of the central nervous system).
    Changes (may increase or decrease) the effect of anticoagulants.
    Reduces the effect of bromocriptine (dose adjustment may be required).
    When used with methyldota increases the risk of developing mental disorders (including disorientation in space, slowing and hindering thinking processes).
    Amphetamines reduce antipsychotic effect of haloperidol, which, in turn, reduces their inducing effect (haloperidol blockade of alpha-adrenoceptors).
    Anticholinergic, antihistamine (1st generation) and antiparkinsonian drugs can enhance the m-cholinoblock effect of haloperidol and reduce its antipsychotic effect (dose adjustment may be required).
    Long-term administration of carbamazepine, barbiturates and other inducers of microsomal oxidation reduces the concentration of haloperidol in plasma.
    In combination with lithium preparations (especially in high doses), the development of encephalopathy (can cause irreversible neurointoxication) and an increase in extrapyramidal symptoms.
    With simultaneous administration with fluoxetine, the risk of side effects from the central nervous system increases, especially extrapyramidal reactions.
    With simultaneous use with drugs that cause extrapyramidal reactions, increases the frequency and severity of ectrapiramid disorders.
    The use of strong tea or coffee (especially in large quantities) reduces the effect of haloperidol.
    Special instructions:During therapy, patients should regularly monitor the ECG, the blood formula, and "liver" tests.
    With the development of tardive dyskinesia, it is recommended that the dose be gradually reduced (until the drug is completely discontinued).
    Care must be taken when performing heavy physical work, taking a hot bath (it is possible to develop a heat stroke due to the suppression of central and peripheral thermoregulation in the hypothalamus).
    During treatment, it is not necessary to take "anti-cold" OTC medicines (there may be an increase in anticholinergic effects and the risk of heat stroke).
    Protect open areas of the skin from excessive sunlight due to the increased risk of photosensitivity.
    Treatment is stopped gradually to avoid the occurrence of the "withdrawal" syndrome.
    An antiemetic effect can mask the signs of drug toxicity and make it difficult to diagnose conditions, the first symptom of which is nausea.
    It was noted that doses for children 6 mg / day cause additional improvement in behavioral disorders and tics.
    Effect on the ability to drive transp. cf. and fur:During the treatment period, care must be taken when driving vehicles and engaging in other potentially hazardous activities that require increased concentration and speed of psychomotor reactions.
    Form release / dosage:
    Tablets of 1.5 mg and 5.0 mg.
    Packaging:
    For 10, 50 tablets in a contour mesh box made of polyvinylchloride film and aluminum foil printed lacquered.
    For 10, 20, 30, 40, 50 or 100 tablets in cans of polyethylene terephthalate or cans of polymeric for medicines.
    One jar or 1, 2, 3, 4, 5, 6, 8 or 10 contour squares, together with the instructions for use, are placed in a cardboard package (bundle).
    Storage conditions:
    In a dry, the dark place at a temperature of no higher than 25 ° C.
    Keep out of the reach of children.
    Shelf life:3 years. Do not use after the expiration date.
    Terms of leave from pharmacies:On prescription
    Registration number:LSR-001488/09
    Date of registration:03.03.2009 / 05.05.2015
    Expiration Date:Unlimited
    The owner of the registration certificate:OZONE, LLC OZONE, LLC Russia
    Manufacturer: & nbsp
    Information update date: & nbsp14.03.2017
    Illustrated instructions
      Instructions
      Up